跳至主要内容
临床试验/NCT00206739
NCT00206739已完成4 期

Intermittent Treatment With Sulfadoxine-pyrimethamine for Malaria Control in Infant: a Randomized, Double-blind, and Placebo-controlled Clinical Trial

Bernhard Nocht Institute for Tropical Medicine1 个研究点 分布在 1 个国家目标入组 1,070 人开始时间: 2003年1月1日最近更新:
适应症
相关药物

试验速览

阶段
4 期
状态
已完成
发起方
入组人数
1,070
试验地点
1
主要终点
• Efficacy of an extended intermittent treatment with sulfadoxine-pyrimethamine for the control of clinical malaria and anemia (proportion and rates of children with one or more episodes of malaria or anemia in the age of 3 to 21 months of life)

研究概览

简要总结

The purpose of this study is to assess the effectiveness of Intermittent Preventive Treatment in Infants (IPTi) with Sulfadoxine-Pyrimethamine to reduce the numbers of malaria attacks, episodes of anemia, and the overall morbidity and mortality

详细描述

In order to define the effectiveness of Intermittent Preventive Treatment in Infants (IPTi) with Sulfadoxine-Pyrimethamine, a novel principle of malaria intervention, the following parameters are evaluated: i) the level of protection from malaria attacks and episodes of anemia during the treatment period, ii) the level of protection from severe malaria during the treatment period, iii) the effect on malaria morbidity after sustaining treatment, iv) the decrease of overall morbidity and mortality, including the number of hospital admissions and visits of hospital outpatient departments v) the influence of the intervention on the development of drug resistances, vi) the impact of the intervention on the development of immunity, vii) the possible influence of the intervention on sub-clinical organ dysfunction due to chronic Plasmodium falciparum infection. Parts of the study are performed in collaboration with the Laboratory of Research, Hospital Albert Schweitzer, Lambaréné, Gabon and the School of Medicine and Health Sciences, University of Development Studies, Tamale, Ghana

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Prevention
盲法
Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)

入排标准

年龄范围
2 Months 至 4 Months(Child)
性别
All
接受健康志愿者

入选标准

  • Informed consent by parent/guardian (written or oral)
  • Permanent residentship in the study area
  • Age of 3 months +/-4 weeks

排除标准

  • Hypersensitivity to sulfonamides or pyrimethamine (skin rashes, evidence of hemolysis including dark urine and/or purpura, presumptive signs of bone marrow depression such as sore throat and/or mouth ulcers)
  • Other severe adverse events related to pyrimethamine-sulfadoxine application
  • Signs of severe hepatic or renal dysfunction not due to malaria
  • Other reasons after decision of the study physician

结局指标

主要结局

• Efficacy of an extended intermittent treatment with sulfadoxine-pyrimethamine for the control of clinical malaria and anemia (proportion and rates of children with one or more episodes of malaria or anemia in the age of 3 to 21 months of life)

• Determination of the rate of clinical malaria and anemia after suspending an extended intermittent treatment for analysis of possible rebound effects

• Evaluation of safety and adverse effects of the administration of single doses of sulfadoxine-pyrimethamine in infants and children

次要结局

  • • Rate and time points of hospitalizations with anemia, malaria or other diseases
  • • Rate and time points of severe anemia episodes
  • • Proportion and rates of children with one or more episodes of malaria or anemia in the age of 3 to 12 months of life
  • • Antibody responses against parasite antigens
  • • Multiplicity of P. falciparum infections
  • • Proportion of P. falciparum isolates with SP resistance
  • • Influence of host genetic variants on the rate of P. falciparum infections

研究者

发起方
Bernhard Nocht Institute for Tropical Medicine
申办方类型
Other Gov

研究点 (1)

Loading locations...

相似试验